Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than a share, Bloomberg News reports
1 min read

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

farman.mansoori.ff@gmail.com0

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Website http://newswave.blog

Related Posts